RxDoctor Payments Data

van Monroe, MD

Interventional Cardiology · Chattanooga, TNNPI 1447259742

Payments from drug & device makers

$1,422in general payments, 2019–2025

Across 72 payments — averaging $19.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$459
  • Medtronic$437
  • Abiomed$200
  • Getinge USA Sales, LLC$88
  • Shockwave Medical, Inc$57
  • Atricure, Inc.$42
  • plus $139 from 7 others

What the payments were for

  • Food & beverage$1,40499%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,422 in reported general payments places this provider in the 10th percentile of 207 interventional cardiology providers in Tennessee.

See all interventional cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$179,715
Medicare patients
1,760
Services billed
3,697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,085$1,066,648
EntrestoSacubitril/Valsartan166$202,723
XareltoRivaroxaban163$161,528
Repatha SureclickEvolocumab42$32,941
JardianceEmpagliflozin26$29,710
FarxigaDapagliflozin Propanediol21$19,529
Prasugrel Hcl92$13,939
Metoprolol Succinate737$13,726
Valsartan231$13,283
Ranolazine ErRanolazine71$12,030
Isosorbide Mononitrate ErIsosorbide Mononitrate604$9,894
BrilintaTicagrelor19$9,670
Rosuvastatin Calcium517$7,253
Atorvastatin Calcium522$6,590
Ezetimibe182$6,551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$459$202,723166 claims
Johnson & JohnsonXarelto$18$161,528163 claims
AstraZenecaFarxiga, Brilinta$12$29,19940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 207 interventional cardiology providers in Tennessee.

Other interventional cardiology in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →